These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. Saito T; Arifin MT; Hama S; Kajiwara Y; Sugiyama K; Yamasaki F; Hidaka T; Arita K; Kurisu K J Neurooncol; 2007 Apr; 82(2):193-8. PubMed ID: 17151933 [TBL] [Abstract][Full Text] [Related]
25. Sohlh1 suppresses glioblastoma cell proliferation, migration, and invasion by inhibition of Wnt/β-catenin signaling. Liu X; Gao Q; Zhao N; Zhang X; Cui W; Sun J; Fu J; Hao J Mol Carcinog; 2018 Apr; 57(4):494-502. PubMed ID: 29240260 [TBL] [Abstract][Full Text] [Related]
26. Transcriptome analysis reveals distinct gene expression profiles in astrocytoma grades II-IV. Narsia N; Ramagiri P; Ehrmann J; Kolar Z Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):261-271. PubMed ID: 28452381 [TBL] [Abstract][Full Text] [Related]
27. Increased β-catenin/Tcf signaling in pilocytic astrocytomas: a comparative study to distinguish pilocytic astrocytomas from low-grade diffuse astrocytomas. Sareddy GR; Geeviman K; Panigrahi M; Challa S; Mahadevan A; Babu PP Neurochem Res; 2012 Jan; 37(1):96-104. PubMed ID: 21922255 [TBL] [Abstract][Full Text] [Related]
28. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells? Bodey B; Bodey B; Siegel SE; Kaiser HE In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378 [TBL] [Abstract][Full Text] [Related]
29. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. Yang I; Han SJ; Sughrue ME; Tihan T; Parsa AT J Neurosurg; 2011 Sep; 115(3):505-11. PubMed ID: 21663411 [TBL] [Abstract][Full Text] [Related]
30. p53 protein and epidermal growth factor receptor expression in human astrocytomas. Kordek R; Biernat W; Alwasiak J; Maculewicz R; Yanagihara R; Liberski PP J Neurooncol; 1995 Oct; 26(1):11-6. PubMed ID: 8583240 [TBL] [Abstract][Full Text] [Related]
31. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Somasundaram K; Reddy SP; Vinnakota K; Britto R; Subbarayan M; Nambiar S; Hebbar A; Samuel C; Shetty M; Sreepathi HK; Santosh V; Hegde AS; Hegde S; Kondaiah P; Rao MR Oncogene; 2005 Oct; 24(47):7073-83. PubMed ID: 16103883 [TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. Arifin MT; Hama S; Kajiwara Y; Sugiyama K; Saito T; Matsuura S; Yamasaki F; Arita K; Kurisu K J Neurooncol; 2006 May; 77(3):273-7. PubMed ID: 16614947 [TBL] [Abstract][Full Text] [Related]
33. Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. Kafka A; Tomas D; Lechpammer M; Gabud T; Pažanin L; Pećina-Šlaus N Dis Markers; 2017; 2017():9253495. PubMed ID: 29200599 [TBL] [Abstract][Full Text] [Related]
34. [Malignancy grading of glial tumors. I. Astrocytomas]. Martin H; Schmidt D Zentralbl Allg Pathol; 1985; 130(6):451-62. PubMed ID: 3010600 [TBL] [Abstract][Full Text] [Related]
35. Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Mohanam S; Wang SW; Rayford A; Yamamoto M; Sawaya R; Nakajima M; Liotta LA; Nicolson GL; Stetler-Stevenson WG; Rao JS Clin Exp Metastasis; 1995 Jan; 13(1):57-62. PubMed ID: 7820957 [TBL] [Abstract][Full Text] [Related]
36. Expression of Fas/APO-1 during the progression of astrocytomas. Tachibana O; Nakazawa H; Lampe J; Watanabe K; Kleihues P; Ohgaki H Cancer Res; 1995 Dec; 55(23):5528-30. PubMed ID: 7585627 [TBL] [Abstract][Full Text] [Related]
37. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. Esen H; Erdi F; Kaya B; Feyzioglu B; Keskin F; Demir LS J Neurooncol; 2015 Feb; 121(3):451-8. PubMed ID: 25391969 [TBL] [Abstract][Full Text] [Related]
38. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078 [TBL] [Abstract][Full Text] [Related]
39. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424 [TBL] [Abstract][Full Text] [Related]
40. Reduced expression of LC3B-II and Beclin 1 in glioblastoma multiforme indicates a down-regulated autophagic capacity that relates to the progression of astrocytic tumors. Huang X; Bai HM; Chen L; Li B; Lu YC J Clin Neurosci; 2010 Dec; 17(12):1515-9. PubMed ID: 20863706 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]